Cases of myocarditis and pericarditis in adolescents and young adults were reported starting in the spring of 2021 after mRNA vaccination, although no causal relationship has been established between vaccination and these adverse events. Reported cases have occurred predominantly in boys and young men aged 16 years and older. The typical onset has been within several days after mRNA COVID-19 vaccination, more often after the second than the first dose. Symptoms and diagnostic findings have included chest pain, elevated cardiac enzymes, and ST- or T-wave changes. Available outcome data indicate that patients generally recover from symptoms of myocarditis or pericarditis. There is still uncertainty about the true rates of myocarditis after mRNA vaccines, but a benefit-risk assessment from the Centers for Disease Control and Prevention concluded in favor of vaccination for all age and sex groups.
Guillain-Barré syndrome is an adverse event that has been reported in people who have received a viral vector vaccine. The cases have largely been reported about 2 weeks after vaccination, mostly in men aged 50 years and older. Rare cases of thrombosis and thrombocytopenia syndrome have also been reported after viral vector vaccination. Women younger than 50 years of age are at increased risk for this rare event. Reports of death after COVID-19 vaccination are also rare, and a causal link has not been established to the vaccines.
Learn more about COVID-19 vaccine safety.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Glenn Wortmann. Fast Five Quiz: COVID-19 Vaccines - Medscape - Oct 15, 2021.
Comments